Mitochondrial respiratory chain deficiency inhibits lysosomal hydrolysis by Fernandez-Mosquera, Lorena et al.
Autophagy
 
Mitochondrial respiratory chain deficiency inhibits lysosomal hydrolysis
--Manuscript Draft--
 
Manuscript Number: KAUP-2018-0173R5
Full Title: Mitochondrial respiratory chain deficiency inhibits lysosomal hydrolysis
Article Type: Research Article
Manuscript Classifications: cell biology; cell signaling; diseases; lysosome; macroautophagy; mammalian
autophagy; mammalian cells; mitochondria; signal transduction; signaling
Abstract: Mitochondria are key organelles for cellular metabolism, and regulate several
processes including cell death and autophagy.
Here, we show that mitochondrial respiratory chain (RC) deficiency deactivates AMP-
activated protein kinase (AMPK, a key regulator of energy homeostasis) signaling in
tissue and in cultured cells. The deactivation of AMPK in RC-deficiency is due to
increased expression of the AMPK-inhibiting protein folliculin.
AMPK is found to be necessary for basal lysosomal function, and AMPK deactivation in
RC-deficiency inhibits lysosomal function by decreasing the activity of the lysosomal
Ca2+ channel Mucolipin-1 (MCOLN1). MCOLN1 is regulated by phosphoinositide
kinase PIKfyve and its product PI(3,5)P2, which is also decreased in RC-deficiency.
Notably, reactivation of AMPK, in a PIKfyve-dependent manner, or of MCOLN1 in RC-
deficient cells, restores lysosomal hydrolytic capacity. Building on these data and the
literature, we propose that down-regulation of the AMPK-PIKfyve-PI(3,5)P2-MCOLN1
pathway causes lysosomal Ca2+ accumulation and impaired lysosomal catabolism.
Besides unveiling a novel role of AMPK in lysosomal function, this study points to the
mechanism that links mitochondrial malfunction to impaired lysosomal catabolism,
underscoring the importance of AMPK and the complexity of organelle cross-talk in the
regulation of cellular homeostasis.
Author Comments: Dear Prof. Klionsky,
We are enclosing the revised manuscript “Mitochondrial respiratory chain deficiency
inhibits lysosomal hydrolysis” with the requested editorial changes in figure 3
(PI(3,5)P2 in the legend changed to PtdIns(3,5)P2) and figure 8 (MCOLN-1 changed to
MCOLN1). I left AMPK as AMPK in the scheme in figure 8 because it we are referring
to the complex.
We hope that the manuscript can now be accepted. We’re looking forward to hear from
you.
Respectfully,
Nuno Raimundo
Order of Authors Secondary Information:
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
Mitochondrial respiratory chain deficiency inhibits lysosomal hydrolysis 
Lorena Fernandez-Mosquera1,2, King F. Yambire1,3,4, Renata Couto1,5, Leonardo 
Pereyra1,5, Kamil Pabis1, Amy H. Ponsford6, Cátia V. Diogo1, Massimiliano Stagi6, Ira 
Milosevic6, Nuno Raimundo1* 
 
1Institute of Cellular Biology, University Medical Center Goettingen, Goettingen, 
Germany 
2Doctoral Program in Molecular Medicine, Georg August University Goettingen, 
Goettingen, Germany 
3International Max-Planck Research School in Neuroscience, Goettingen, Germany 
4European Neuroscience Institute (ENI) and University Medical Center Goettingen, 
Goettingen, Germany 
5Doctoral Program in Molecular Biology of the Cells, Göttingen Graduate School for 
Neurosciences, Biophysics, and Molecular Biosciences, University of Goettingen, 
Goettingen, Germany 
6Institute of Translational Medicine, University of Liverpool, Liverpool, United 
Kingdom 
 
*corresponding author, nuno.raimundo@med.uni-goettingen.de 
 
RUNNING TITLE: Mitochondrial malfunction impairs lysosomes 
 
KEYWORDS: AMPK, calcium, lysosomal Ca2+, lysosomes, MCOLN1, mitochondria, 
mitochondrial respiratory chain deficiency   
Manuscript - with full author details
ABSTRACT 
Mitochondria are key organelles for cellular metabolism, and regulate several processes 
including cell death and macroautophagy/autophagy.  Here, we show that mitochondrial 
respiratory chain (RC) deficiency deactivates AMP-activated protein kinase (AMPK, a key 
regulator of energy homeostasis) signaling in tissue and in cultured cells. The deactivation of 
AMPK in RC-deficiency is due to increased expression of the AMPK-inhibiting protein FLCN 
(folliculin). AMPK is found to be necessary for basal lysosomal function, and AMPK 
deactivation in RC-deficiency inhibits lysosomal function by decreasing the activity of the 
lysosomal Ca2+ channel MCOLN1 (mucolipin 1). MCOLN1 is regulated by phosphoinositide 
kinase PIKFYVE and its product PtdIns(3,5)P2, which is also decreased in RC-deficiency. 
Notably, reactivation of AMPK, in a PIKFYVE-dependent manner, or of MCOLN1 in RC-
deficient cells, restores lysosomal hydrolytic capacity. Building on these data and the 
literature, we propose that downregulation of the AMPK-PIKFYVE-PtdIns(3,5)P2-MCOLN1 
pathway causes lysosomal Ca2+ accumulation and impaired lysosomal catabolism. Besides 
unveiling a novel role of AMPK in lysosomal function, this study points to the mechanism that 
links mitochondrial malfunction to impaired lysosomal catabolism, underscoring the 
importance of AMPK and the complexity of organelle cross-talk in the regulation of cellular 
homeostasis.  
  
Abbreviation List 
ΔΨm – mitochondrial transmembrane potential  
AMP - adenosine monophosphate  
AMPK - AMP-activated protein kinase  
ATG5 – autophagy related 5 
ATP - adenosine triphosphate  
ATP6V0A1 - ATPase, H+ transporting, lysosomal, V0 subbunit A1  
ATP6V1A - ATPase, H+ transporting, lysosomal, V0 subbunit A 
BSA - bovine serum albumin  
CCCP - carbonyl cyanide-m-chlorophenylhydrazone  
CREB1 – cAMP response element binding protein 1 
CTSD - cathepsin D  
CTSF - cathepsin F  
DMEM - Dulbecco’s modified Eagle’s medium  
DMSO – dimethyl sulfoxide  
EBSS - Earl’s balanced salt solution  
ER - endoplasmic reticulum  
FBS - fetal bovine serum  
FCCP - carbonyl cyanide-p-trifluoromethoxyphenolhydrazone  
GFP - green fluorescent protein  
GPN - glycyl-L-phenylalanine 2-naphthylamide 
LAMP1 - lysosomal associated membrane protein 1  
MAP1LC3B/LC3B - microtubule associated protein 1 light chain 3 beta  
MCOLN1/TRPML1 - mucolipin 1  
MEF – mouse embryonic fibroblast 
MITF - melanocyte inducing transcription factor 
ML1N*2-GFP – probe used to detect PtdIns(3,5)P2 based on the transmembrane domain of MCOLN1 
MTORC1 - mechanistic target of rapamycin kinase complex 1  
NDUFS4 - NADH:ubiquinone oxidoreductase subunit S4 
OCR - oxygen consumption rate  
PBS - phosphate-buffered saline  
pcDNA - plasmid cytomegalovirus promoter DNA  
PCR - polymerase chain reaction  
PtdIns3P - phosphatidylinositol-3-phosphate  
PtdIns(3,5)P2 - phosphatidylinositol-3,5-bisphosphate  
PIKFYVE - phosphoinositide kinase, FYVE-type zinc finger containing  
P/S - penicillin-streptomycin  
PVDF - polyvinylidene fluoride  
qPCR - quantitative real time polymerase chain reaction  
RFP - red fluorescent protein  
RNA - ribonucleic acid  
SDS-PAGE - sodium dodecyl sulfate polyacrylamide gel electrophoresis  
shRNA - short hairpin RNA  
siRNA - small interfering RNA  
TFEB - transcription factor EB  
TFE3 - transcription factor binding to IGHM enhancer 3 
TMRM - tetramethylrhodamine, methyl ester, perchlorate 
ULK1 - unc-51 like autophagy activating kinase 1  
ULK2 - unc-51 like autophagy activating kinase 2  
UQCRC1 - ubiquinol-cytochrome c reductase core protein 1  
v-ATPase - vacuolar-type H+-translocating ATPase  
WT – wild-type 
 
  
INTRODUCTION 
Mitochondria are multi-tasking cellular organelles with key roles in energy metabolism [1]. 
Their importance for cell biology, however, extends beyond metabolism. These organelles 
are powerful signaling platforms regulating processes such as cell proliferation, 
differentiation, death, as well as autophagy [2-4]. 
Autophagy is a process of intracellular self-digestion that is used to recycle damaged or 
excessive cellular components, by sequestering them within cytoplasmic double-membrane 
compartments, termed autophagosomes [5]. The autophagosomes subsequently fuse with 
the lysosomes (organelles containing degradative enzymes that can break down many 
proteins and biomolecules), allowing the contents of the autophagosomes to be degraded by 
lysosomal hydrolases [5]. The process of autophagy is highly regulated at several steps, in 
particular at the level of autophagosome formation and degradation of autophagosomal 
cargo. Autophagosome formation is regulated by protein kinase A and by the AMPK-
MTORC1-ULK1/2 signaling axis in response to amino acid availability and cellular energy 
charge [6,7]. Lysosomal-mediated autophagosomal degradation is regulated by several 
transcription factors (e.g., CREB, TFEB, MITF, TFE3) that promote the expression of a large 
set of genes encoding lysosomal proteins (lysosomal biogenesis), ultimately resulting in 
increased number and hydrolytic capacity of the lysosomes [8,9].  
The energy-sensing AMPK (AMP-dependent protein kinase) is an important integrator of 
energy and metabolic cues [10,11]. It responds to energy stress caused by depletion in 
cellular ATP levels, for example as a result of acute inhibition of the mitochondrial respiratory 
chain or under glucose deprivation, as well as to cytoplasmic Ca2+ levels, reactive oxygen 
species and other stimuli [10]. In addition to activation of autophagosome formation, AMPK 
stimulates both mitochondrial and lysosomal biogenesis [11-13]. Persistent activation of 
AMPK can, however, trigger apoptosis in vitro and in vivo [14-16]. The metabolic and 
signaling roles of AMPK place it at the crossroads between mitochondrial function and 
autophagy. 
The interplay between mitochondria and autophagy is often focused on how mitochondria 
are regulated via mitophagy, i.e., selective autophagy of mitochondria [17]. However, 
mitochondria also regulate the autophagy pathway, independently of mitophagy, in particular 
by regulating autophagosome formation [18,19]. Nevertheless, it remains unclear how 
autophagosome digestion is impacted in mitochondrial deficiency.  
In the present study, we show that mitochondrial respiratory chain deficiency inhibits 
lysosomal hydrolysis. This prominent defect can be fully rescued by re-activation of AMPK 
signaling, or by direct activation of the lysosomal Ca2+ channel MCOLN1 (mucolipin 1). 
Importantly, we also show AMPK has a role in the regulation of basal lysosomal function, 
mediated by the generation of PtdIns(3,5)P2 and MCOLN1 activity. These results place 
AMPK at the core of a regulatory mechanism coordinating mitochondria-lysosome interplay. 
  
RESULTS 
Chronic mitochondrial respiratory chain deficiency leads to accumulation of 
autophagosomes  
To study the consequences of chronic mitochondrial respiratory chain malfunction on the 
autophagy pathway, we prepared a cellular model of chronic respiratory chain deficiency by 
a stable shRNA-mediated knockdown of a subunit of respiratory chain complex III (UQCRC1/ 
[ubiquinol-cytochrome c reductase core protein 1]) in HeLa cells (hereafter referred to as 
respiratory chain knockdowns or RC-kds). shRNAs with scrambled sequence were used as 
controls (HeLa scrambled). We tested 5 different shRNA constructs, of which we selected 
the 2 with the strongest knockdown efficiency evident both at protein (Fig. S1A) and 
transcript levels (Fig. S1B). These RC-kds cells showed a robust decrease in oxygen 
consumption rate (OCR) (Fig. S1C, quantified in S1D), and an increase in superoxide levels, 
as assessed by the superoxide-sensitive dye MitoSOX (Fig. S1E). The potential across the 
mitochondrial membrane (Δψm) was found to be modestly yet significantly decreased (Fig. 
S1F), as assessed by the ratio between MitoTracker Red (imported to mitochondria in a 
Δψm-dependent manner) and MitoTracker Green (imported independently of Δψm). The 
mitochondrial impairment in RC-kds was comparable to control cells treated with a complex 
III inhibitor, antimycin (Fig. S1G), and more moderate than treatment with the uncoupler 
FCCP (Fig. S1F-S1G). Altogether, these data show that the RC-kds cells have chronic 
respiratory chain malfunction. 
To assess the effect of mitochondrial respiratory chain malfunction on the autophagy 
pathway, we first expressed a green fluorescent protein (GFP)-tagged autophagosomal 
marker protein, MAP1LC3B/LC3B (microtubule associated protein 1 light chain 3 beta) (GFP-
LC3B), to determine the abundance of autophagosomes in RC-kd cells and controls. 
Increased numbers of autophagosomes were observed in the RC-kd cells (Fig. 1A), and their 
size was also mildly enlarged. To validate this observation, we measured the protein levels of 
the autophagosomal marker LC3B-II by western blot: the RC-kds cells presented increased 
levels of LC3B-II (Fig. 1B). Given that both RC-kds were behaving similarly, we focused on 
RC-kd1 (henceforth referred to as RC-kd) for a more detailed follow-up. We also observed 
increased GFP-LC3 signal in RC-kd by flow cytometry (Fig. S2A), further confirming the 
increased autophagosomal mass in RC-kds.  
The accumulation of autophagosomes in the cell results from an imbalance between 
autophagosome formation and degradation. To determine whether autophagosome 
degradation was affected, we co-expressed LAMP1 (lysosomal associated membrane 
protein 1)-GFP and RFP-LC3, markers for lysosomes and autophagosomes, respectively. 
While in the control cells almost no RFP-LC3-positive signal was found inside lysosomes 
(Fig. 1C, upper panel), the RC-kd cells showed a robust accumulation of undigested RFP-
LC3 in LAMP1-GFP-positive compartments (Fig. 1C, middle panel), suggesting that 
undigested RFP-LC3 remains inside lysosomes. Curiously, when control cells were treated 
with the lipophilic base chloroquine, which inhibits lysosomal acidification, a similar effect 
was observed, with prominent accumulation of undigested RFP-LC3 signal inside the 
LAMP1-GFP-positive lysosomal membrane (Fig. 1C, bottom panel).  
In addition to the undigested RFP-LC3-positive content, the lysosomes in RC-kd cells 
appeared enlarged (Fig 1C, middle panel). To examine lysosomal morphology in more detail, 
we detected LAMP1 in RC-kd and control cells by immunocytochemistry, and observed that 
while the number of LAMP1-positive compartments was not affected (Fig. S2B), the average 
size of LAMP1-positive puncta, indicating lysosomal volume, was significantly increased in 
the RC-kd (Fig. 1D, quantification in the upper right panel). Specifically, the population of 
smaller LAMP1-positive lysosomes decreased in RC-kd, while the presence of larger 
LAMP1-positive lysosomes increased (Fig. 1D, lower right panel). The protein extracts from 
RC-kd cells also showed an increase in the protein levels of lysosomal proteins, namely 
LAMP1 (Fig. S2C), and the lysosomal v-ATPase components ATP6V0A1 and ATP6V1A 
(Fig. S2D) in comparison to controls, showing that the RC-kd cells have increased levels of 
lysosomal proteins per cell. Finally, we also observed an increase in LysoTracker dye 
intensity in the RC-kd cells, as measured by flow cytometry (Fig. S2E). Interestingly, the 
phenotype that we have detected in RC-kd cells is reminiscent to the described lysosomal 
phenotype in Niemann-Pick lysosomal storage disease, in which increased intensity upon 
lysosomal staining with the dye LysoTracker was established as a biomarker for lysosomal 
enlargement [20].  
To exclude the possibility that these observations were an artifact of a clonal HeLa cell line 
and specific knock-down of UQCRC1 or of a subunit of respiratory chain complex III, we 
tested mouse embryonic fibroblasts (MEFs) lacking a subunit of respiratory chain complex I, 
ndufs4-/-, and the corresponding wild-type (WT) littermates. As observed in the RC-kd cells, 
the ndufs4-/- MEFs presented similar number of slightly enlarged LAMP1-immunostained 
lysosomes (Fig. S2F) and robustly increased LysoTracker intensity (Fig. S2G), indicating that 
the effect of chronic mitochondrial respiratory chain malfunction on lysosomal function is 
conserved across different cell lines, in accordance with our previous study [13]. 
Lysosomes and lysosome-related organelles have a specific morphological signature that is 
best appreciated by high-resolution ultrastructural analysis using electron microscopy (EM) 
[21]. Thus, we performed detailed EM-based analysis of RC-kd and control cells grown under 
standard cell culture conditions. The abnormality in lysosome morphology was strongly 
evidenced by electron micrographs, in which enlarged structures with electron-dense 
contents were abundantly and frequently observed in RC-kd while rarely detected in control 
cells (Fig. 1E, quantification of size and distribution in the right panel), in agreement with our 
data obtained by light microscopy imaging and biochemistry. 
It is possible that the lysosomal enlargement observed in RC-kd cells by various methods 
could be caused by excessive delivery of autophagosomal cargo. To test this possibility, we 
silenced the expression of ATG5 (autophagy related 5) protein, which is essential for the 
formation of the autophagosomes [22]. Silencing of ATG5 in both RC-kd and control cells by 
siRNA increased the lysosomal size in both conditions (Fig. 1F), suggesting that the 
lysosomal enlargement observed in RC-kd was not caused by excessive trafficking of 
autophagosomal cargo.  
Mitochondrial respiratory chain malfunction impairs lysosomal function by repressing 
the lysosomal Ca2+ channel MCOLN1 
Because the enlargement of lysosomes in RC-kd cells did not appear to be a result of 
excessive delivery of autophagosomal cargo, and given that lysosomal defects often result in 
enlarged lysosomes [20, 23, 24], we hypothesized that lysosomal function per se was 
impaired. The lysosomes have several diverse roles in cellular metabolism and homeostasis, 
particularly in hydrolysis of complex lipids and proteins as well as Ca2+ storage, that all 
depend on acidic lumenal pH [25]. We probed lysosomal pH by using 2 complementary 
dextran-conjugated dyes (with the same molecular weight), which are endocytosed by the 
cell and accumulate selectively in the lysosomes. One set of dextran molecules is conjugated 
with Oregon Green, whose emission is quenched under acidic environments such as the 
lysosomal lumen, while the other is conjugated with TMRM, whose emission in the red 
spectrum is pH independent [26]. Therefore, by determining the ratio between the green and 
red dextran-coupled fluorophores, it is possible to monitor the changes in lysosomal pH 
(more acidic, lower green:red ratio; less acidic, higher green:red). We verified these 
properties of the dextrans by setting the lysosomal pH in control cells at pH 4.0, pH 7.0 and 
pH 10.0. The green fluorescence was barely detectable at pH 4.0, while increasingly 
noticeable at neutral (pH 7.0) and alkaline (pH 10.0) pH (Fig. S3A). Accordingly, treatment of 
scrambled cells with the v-ATPase inhibitor bafilomycin A1 resulted in clear lysosomal 
alkalinization, as shown by a strong increase in the green dextran (Fig. S3A).The RC-kd cells 
presented a much higher green:red ratio than the control cells, indicating a lysosomal pH 
close to neutral (Fig. 2A, Fig. S3A).  
To assess if the increased pH had an impact in lysosomal proteolytic activity, we loaded the 
control and both RC-kd cell lines (to verify whether both RC-kd lines behave comparably also 
in key functional assays) with polymeric bovine serum albumin labelled with a green BODIPY 
dye (DQ Green BSA green; the assay is based on the fact that the high amount of 
fluorophore in polymeric DQ Green BSA has a quenching effect). Cells take up DQ Green 
BSA by endocytosis and it accumulates in the lysosomes [27]. As the lysosomal proteases 
hydrolyze DQ Green BSA into small peptides, in which the fluorescence is no longer 
quenched, the fluorescent monomers accumulate and an increase in fluorescence is 
observed (Fig. 2B). In addition, the rate of this fluorescence increase is proportional to the 
activity of the lysosomal proteases. Both RC-kd1 and RC-kd2 also had a lower rate of DQ 
Green BSA hydrolysis, suggesting a decrease in the activity of lysosomal proteases in situ 
(Fig. 2B). We obtained a similar result using DQ Red BSA, thus discounting the possibility 
that the lower DQ-BSA hydrolysis rate was an artifact of fluorophore detection due to a 
different lumenal pH in the RC-kd cells (data not shown). To exclude the possibility that the 
DQ-BSA result was affected by possible differential uptake of DQ-BSA in the RC-kd versus 
control cells, we also employed the Magic Red assay. This dye diffuses through cellular 
membranes and therefore cannot be affected by possible differential endocytic rates. When 
Magic Red is activated by cathepsins in the lysosome, the product triggers a red fluorescent 
signal. The RC-kd cells also had lower Magic Red fluorescence, supporting decreased 
lysosomal cathepsin activity (Fig. S3B). Importantly, the treatment of control cells with the 
lysosomal inhibitor chloroquine results in decreased Magic Red intensity (Fig. S3B) as well 
as decreased DQ-BSA degradation (Fig. S3C), thus validating the use of these assays and 
supporting decreased lysosomal proteolytic function in RC-kd cells. It is noteworthy that the 
ndufs4-/- MEFs also showed decreased lysosomal DQ-BSA degradation (Fig. S2H).  
The lysosomal storage of Ca2+ also depends on the acidic pH [28], therefore we assessed 
the lysosomal Ca2+ levels ([Ca2+]L). We exposed the RC-kd and control cells to glycyl-L-
phenylalanine 2-naphthylamide (GPN), a compound that when activated in the lysosomal 
lumen by CTSC (cathepsin C) forms pores in the lysosomal membrane through which Ca2+ 
and other lysosomal components are released [29]. We monitored the changes in 
cytoplasmic [Ca2+] upon lysosomal permeabilization using membrane-permeable Ca2+-
sensitive dye, Fluo-4 AM (Fig. 2C). Interestingly, upon permeabilization, lysosomes in RC-kd 
cells release on average ~4-5-fold more Ca2+ to the cytoplasm than control cells (Fig. 2D). 
Representative time-lapse images of Fluo-4-stained control and RC-kd cells are presented in 
Video SV1. This result is unexpected given that it is widely accepted that when lysosomal pH 
increases, the organelle releases Ca2+ in the cytosol [28]. Importantly, pre-treatment of the 
cells with xestospongin C, an inhibitor of Ca2+ release through ITPRs/IP3 receptors in the 
endoplasmic reticulum, had no effect on the GPN-induced lysosomal Ca2+ release (Fig. 2C). 
These data exclude the possibility that Ca2+ from the endoplasmic reticulum was a 
confounding factor. Therefore, Ca2+ accumulates in the lysosomes in RC-kd cells. Given that 
this occurs under conditions of neutral lysosomal pH, it implies that the conventional 
mechanisms of lysosomal Ca2+ release are impaired. Thus, we tested the properties of 
lysosomal Ca2+ release in the RC-kd model. 
Lysosomes have several Ca2+ channels, including 2 large families of MCOLN and two-pore 
channels. The loss-of-function, or the deletion, of one of the MCOLN channels, MCOLN1 
(mucolipin 1), result in enlarged lysosomes, lysosomal Ca2+ accumulation and increased pH 
[24], all of which are observed in the RC-kd cells. Furthermore, MCOLN1 is the only 
lysosomal Ca2+ channel that is required for autophagy and lysosomal biogenesis, via 
activation of PPP3/calcineurin and TFEB (transcription factor EB) [30] [31]. Interestingly, 
unlike control cells, neither the RC-kd cells (Fig. S4A), nor ndufs4-/- MEFs (Fig S4B), were 
able to induce lysosomal biogenesis, both under basal conditions, or upon amino acid 
starvation. Given the curious overlap between the cellular phenotypes of MCOLN1 loss-of-
function and the RC-kd lines, we tested the possibility that MCOLN1 abundance and/or 
function is altered in the RC-kd lines. To first test if the accumulation of lysosomal Ca2+ in 
RC-kd lines was related with MCOLN1, we treated the cells with the MCOLN1-specific 
activator MLSA1 [32] 20 µM for 4 h (or DMSO as control), and most interestingly observed 
that the lysosomal Ca2+ levels in the RC-kd lines were returned to the values comparable to 
the control line (Fig. 2D; representative time-lapses in Video SV1; note that no effect of 
MLSA1 was observed on the control cells). Given that both RC-kd cell lines gave similar 
results in all functional assay that assess lysosomal proteolysis and Ca2+, we proceeded 
again with just one RC-kd (RC-kd1) line. Notably, the protein levels of MCOLN1 were not 
altered in the RC-kd cells (Fig. 2E), suggesting that the accumulation of Ca2+ in lysosomes is 
due to aberrant MCOLN1 activity. Interestingly, we observed that reactivation of MCOLN1 in 
RC-kd cells, by treatment with MLSA1, also allowed the lysosome to reacidify (Fig. S3A). 
We next sought to determine if increasing the activity of MCOLN1 and normalizing the 
lysosomal Ca2+ levels and pH was sufficient to rescue the lysosomal enlargement in RC-kd 
cell lines. Thus, we treated the control and RC-kd cells with MLSA1 20 µM for 4 h (or DMSO 
as control), and inspected lysosomal morphology by antibody staining against LAMP1. We 
observed, as before, that lysosomes were enlarged in RC-kd, but remarkably MLSA1 
treatment restored lysosomal volume to the control values (Fig. 2F; the MLSA1 treatment per 
se had no effect on the lysosomal volume in control cells). These data show that reactivation, 
or increased activity, of MCOLN1 channel is sufficient to normalize both lysosomal 
morphology, Ca2+ levels and pH in RC-kd cells. 
To test whether the normalization of lysosomal volume caused by MCOLN1 activation in RC-
kd cells had impacted lysosomal function, we employed the DQ-BSA and Magic Red 
functional assays. Indeed, RC-kds treated with MLSA1 to reactivate MCOLN1 showed an 
improvement in lysosomal activity to control levels, both as assessed by Magic Red (Fig. 
S3B) and by DQ-BSA (Fig. S3C). We further confirmed this result with another functional 
assay based on acridine orange. Acridine orange is a lipophilic amine, which freely diffuses 
across the cell. Upon repeated exposure to blue light in the acidic environment of the 
lysosome, acridine orange becomes phototoxic, damaging the lysosomal membrane and 
eventually causing its rupture [33]. The lysosomal acridine orange then leaks into the neutral 
cytoplasmic pH, where its fluorescence emission is shifted from red to green [34, 35]. 
Discrete events of lysosomal disintegration can be observed in time lapse imaging, as shown 
in Video SV2 (top row, control cells; medium row, RC-kd cells; bottom row, RC-kd cells 
treated with MLSA1). The kinetics of lysosomal disintegration due to acridine orange 
phototoxicity is slower when the lysosomes are impaired [35]. We observed that the control 
cells lost acridine orange lysosomal fluorescence in ~60 s (Fig. S5A). Yet, the RC-kd cells 
retained lysosomal acridine orange fluorescence even at ~120 s (Fig. S5A), and this was 
corrected by activation of MCOLN1 using MLSA1 (Fig. S5A). The disappearance of 
lysosomal acridine orange signal in a representative organelle for each condition is depicted 
in Fig. S5B. Overall, the loss of lysosomal acridine orange was significantly slower in the RC-
kd cells, in line with our data showing that lysosomal function is impaired in RC-kd cells. The 
treatment of RC-kd cells with MLSA1 was able to normalize the function of lysosomes (Fig. 
S5C). These data also illustrate the consequences of impaired MCOLN1 activity for 
lysosomal function in RC-kd cells.  
Notably, the accumulation of Ca2+ in the lysosomes of RC-kd cells has consequences for the 
cellular Ca2+ homeostasis, because cytoplasmic Ca2+ levels appeared to be decreased in 
RC-kd and were returned to control levels after MCOLN1 activation by MLSA1 treatment, as 
assessed by intensity of the cytoplasmic Ca2+-dye Fluo-4 in basal conditions (Fig. 2G). 
Altogether, these data show that Ca2+ accumulation in lysosomes of RC-kd cells is due to 
reduced or abolished MCOLN1 activity, which also has consequences for cellular Ca2+ 
homeostasis because it affects Ca2+ levels both in the lysosome (excess Ca2+) and in the 
cytoplasm (decreased Ca2+).  
 
Downregulation of MCOLN1 is caused by decreased AMPK signaling 
The activity of MCOLN1 is stimulated by PtdIns(3,5)P2, which is synthesized by the enzyme 
PIKFYVE in the lysosomal membrane [36]. AMPK has been suggested to activate PIKFYVE 
[37], and is also a known responder to mitochondrial stress [10]. Given that the RC-kd cells 
show accumulation of lysosomal Ca2+ and decreased activity of MCOLN1, we set to test 
whether AMPK may control the activity of MCOLN1 via the PIKFYVE-PtdIns(3,5)P2-MCOLN1 
pathway (Fig. 3A). Despite HeLa cells lacking the LKB1 protein [38], which is necessary for 
activation of AMPK by AMP [39], it has been shown that AMPK gets activated in response to 
energy stress in these cells [40], which therefore can be employed as a model.  
First, we tested if we could observe a direct interaction between AMPK and PIKFYVE. We 
immunoprecipitated AMPK, and could detect PIKFYVE as one of its interactors (Fig. 3B). 
However, the amount of PIKFYVE interacting with the AMPK alpha subunits was similar in 
RC-kd and control cells (Fig. 3B, lanes 3-4 for scrambled and 5-6 for RC-kd). Thus, AMPK 
interacts with PIKFYVE to a similar extent in control and RC-kd cells, and therefore this 
interaction alone cannot explain a decrease in the PIKFYVE-MCOLN1 pathway in RC-kd 
cells. 
We then tested if AMPK activity is affected in RC-kd cells. Using western blotting, we found 
that phosphorylation of AMPK Thr172, which is indicative of its activity, was decreased in 
RC-kd cells, suggesting that AMPK signaling was downregulated (Fig. 3C). Accordingly, 
phosphorylation of AMPK-target site Ser1387 in TSC2 (tuberous sclerosis complex 2) was 
also decreased in RC-kd cells, substantiating decreased AMPK activity in these cells (Fig. 
3C). Interestingly, when scrambled HeLa were treated for 4 h with antimycin (an inhibitor of 
respiratory chain complex III), there was an increase in AMPK activity, as assessed by 
phosphorylation of AMPK and its target TSC2 (Fig. S6A). However, the same treatment in 
the RC-kd cells has no effect on AMPK activity (Fig. S6A). These results highlight that HeLa 
cells can activate AMPK in response to energy stress, a response that is impaired in the RC-
kd cells. 
Because MCOLN1 function is defective in RC-kd cells, and MCOLN1 is regulated by the 
PIKFYVE-PtdIns(3,5)P2-MCOLN1 pathway, we hypothesized that the decrease in AMPK 
activity might result in depression of the PIKFYVE-PtdIns(3,5)P2-MCOLN1 pathway, thus 
impairing lysosomal function. Indeed, the inability of a cell to synthesize PtdIns(3,5)P2 due to 
defects in PIKFYVE or associated enzymes results in enlarged lysosomes [41]. Accordingly, 
treatment with 1 µM of the PIKFYVE inhibitor YM201636 for 4 h caused lysosomal 
enlargement in both control and RC-kd cells (Fig. S7). 
We subsequently assessed whether the observed decrease in AMPK signaling has 
consequences for the levels of PtdIns(3,5)P2. We assessed PtdIns(3,5)P2 using a genetic 
probe consisting of the transmembrane segment of MCOLN1 fused with GFP (ML1N*2-GFP) 
[42]. This is the region of MCOLN1 that interacts with PtdIns(3,5)P2 [42], and therefore the 
probe is expected to be recruited to the membranes where PtdIns(3,5)P2 is present (which is 
mostly the lysosomal membrane) in a manner proportional to the amount of lipid. To control 
for the possibility of mislocalization of the ML1N*2-GFP probe [43], we co-expressed it with 
the lysosomal marker LAMP1-RFP. First, as a control for PtdIns(3,5)P2 specificity, we tested 
if the signal was decreased upon PIKFYVE inhibition. We treated scrambled cells with the 
PIKFYVE inhibitor YM201636 1 µM 4 h, and observed that the ML1N*2-GFP probe 
presented a weak, diffuse staining (Fig. 3D). This result suggests that in the conditions we 
are employing, the ML1N*2-GFP probe seems specific for PtdIns(3,5)P2. We further 
observed that the intensity of the ML1N*2-GFP signal in the lysosome (areas of overlap 
between LAMP1-RFP and ML1N*2-GFP; GFP intensity measured) was lower in RC-kd cells 
compared to control cells, suggesting decreased amounts of PtdIns(3,5)P2 in the lysosomal 
membranes of RC-kd cells (Fig. 3D). This was not a consequence of decreased amounts of 
PIKFYVE protein in RC-kd cells (Fig. 3C), therefore PIKFYVE is likely inhibited under these 
conditions. Interestingly, one of the most prevalent cellular phenotypes of loss of PIKFYVE 
activity is the accumulation of undigested contents in the lysosomes [41, 44], consistent with 
our observations in RC-kd cells. 
We then tested if reactivating AMPK signaling in the RC-kd cells, with the compound 
A769662, a widely accepted specific activator of AMPK [45], would lead to an increase in 
PtdIns(3,5)P2 levels. This compound activates AMPK independently of STK11/LKB1, and 
therefore is also effective in HeLa cells [46]. We observed that the activation of AMPK 
restores the levels of PtdIns(3,5)P2 in the RC-kd to control levels, as assessed by co-
expression of ML1N*2-GFP and LAMP1-RFP (Fig. 3D). Altogether, these data suggest that 
AMPK signaling regulates, at least in part, the production of PtdIns(3,5)P2 and, through it, the 
activity of MCOLN1. 
 
Downregulation of AMPK signaling in RC-kd is caused by the induction of FLCN 
expression 
Since AMPK signaling is usually found to be increased in response to acute mitochondrial 
respiratory chain malfunction, the decreased AMPK activity observed in RC-kd might seem 
counterintuitive. Therefore, we sought first to test what happens to the AMPK signaling in an 
in vivo system of chronic mitochondrial respiratory chain malfunction. The ndufs4-/- mice are 
a model of mitochondrial dysfunction that results in disease characterized by encephalopathy 
and prematurely dying at ~7 weeks of age [47]. We used brain homogenates from ndufs4-/- 
mice and their WT littermates to probe the AMPK pathway by western blot, and found that 
AMPK signaling, as assessed by the phosphorylation of AMPK target ACAC/ACC (acetyl-
CoA carboxylase), was downregulated in the ndufs4-/- brain (Fig S8A, quantified in S8B). 
Therefore, the decreased AMPK signaling in RC-kd cells is consistent with downregulation of 
AMPK signaling under chronic mitochondrial respiratory chain malfunction. 
Next, we explored the reasons underlying AMPK downregulation. The termination of AMPK 
signaling is poorly studied, and to our knowledge the only protein known to directly inhibit 
AMPK activity is the tumor-suppressor FLCN. FLCN forms a heterotrimer with FNIP1 
(folliculin interacting protein 1) and FNIP2, and such a complex inhibits AMPK activity [48]. In 
support of decreased AMPK activity in the RC-kds cells, FLCN and FNIP1 proteins were 
more abundant in whole cell extracts of RC-kds (Fig. 4A). This may result from increased 
transcription, because the transcripts of FLCN, FNIP1 and FNIP2 were all upregulated in RC-
kds (Fig. 4B). To test if FLCN is directly responsive to mitochondrial stress, we treated 
control cells with an inhibitor of mitochondrial respiratory chain complex III, antimycin, for 
short (1-4 h) and long (48 h) periods. We observed that the protein levels of FLCN and FNIP 
remained mostly unaltered during the acute treatments, but were robustly increased by the 
long-term mitochondrial respiratory chain inhibition (Fig. S6B). Notably, the transcript levels 
of FLCN, FNIP1 and FNIP2 were downregulated during the acute treatments, but 
upregulated after 48 h of treatment (Fig. S6C). FNIP2 was also downregulated in acute 
inhibition but remained unaffected in the long-term treatment (Fig. 4B and Fig. S6C). Thus, 
the transcript levels of FLCN and FNIP1 were responsive to long-term mitochondrial 
respiratory chain deficiency, both in the RC-kd cells and under pharmacological inhibition 
(antimycin). 
We tested 2 antibodies against FLCN and FNIP1 in mouse cells and tissues, yet they did not 
work and/or were not specific in our hands. Because in the RC-kds the upregulation in 
expression of FLCN, FNIP1 and FNIP2 was also observed at transcript levels, we tested 
their transcript levels in ndufs4-/- MEFs and brain. We observed an upregulation of the 
transcript levels of Flcn, Fnip1 and Fnip2 in ndufs4-/- MEFs (Fig. S6D), and of Flcn and Fnip1 
in ndufs4-/- brain (Fig. S6E). Altogether, these results suggest that FLCN induction is a 
specific consequence of chronic, but not acute, mitochondrial respiratory chain impairment. 
We then tested if silencing of FLCN might be beneficial for the RC-kds cells, using siRNA. 
First, we observed that the siRNA against FLCN was efficient (Fig. 4C). The activity of AMPK 
was clearly induced by the silencing of FLCN (Fig. 4C), as assessed by the phosphorylation 
of AMPK and of its target TSC2. This result is in agreement with the known repressor role of 
FLCN on AMPK, and underscores that silencing of FLCN in RC-kd cells was sufficient to 
return AMPK activity to control levels. Notably, the partial silencing of FLCN yielded a much 
stronger effect in AMPK in the RC-kd cells than in the controls.  
Next, we tested if the silencing of FLCN had beneficial effects on lysosomal function. We 
assessed lysosomal size by immunohistochemistry against LAMP1, and observed that 
silencing FLCN in RC-kd cells returned lysosomal size to control levels (Fig. 4D). 
Interestingly, silencing of FLCN in scrambled cells resulted in a trend for lysosomal 
enlargement, underscoring that forcing the levels of FLCN to go below the baseline has 
negative consequences (Fig. 4D). The acidification of the lysosome was comparable to 
control levels in RC-kd with FLCN silencing (Fig. 4E). Curiously, the silencing of FLCN in RC-
kds cells caused an increase in the expression of lysosomal genes (Fig. S6E), indicating a 
normalization of the lysosomal Ca2+ efflux through MCOLN1, necessary for TFEB activity 
[30]. However, despite the silencing of FLCN in RC-kd being sufficient to rescue lysosomal 
size and pH, the activity of the lysosomes as assessed by DQ-BSA remained unaffected 
(Fig. S6F) in RC-kds, and decreased robustly in control cells, underscoring that efficient 
lysosomal function can only occur within a limited range of folliculin levels. 
AMPK is required for basal lysosomal function 
The decrease in AMPK signaling observed in RC-kd and the downstream consequences for 
PIKFYVE and MCOLN1 suggest that AMPK might have a role in the regulation of lysosomal 
function. To test if this role takes place exclusively during chronic mitochondrial stress or also 
under basal conditions, we took advantage of MEFs lacking AMPK activity. AMPK functions 
as a heterotrimer, containing 1 catalytic (PRKAA/α) subunit and 2 regulatory subunits 
(PRKAB/β and PRKAG/). Mammals have 2 genes encoding the catalytic α subunit, 
PRKAA1 and PRKAA2 [49]. To test if loss of AMPK activity is sufficient to impair lysosomal 
function, we used MEFs with defective or absent AMPK activity, derived from knockouts of 
the genes encoding the catalytic subunits, Prkaa1, Prkaa2 or Prkaa1 Prkaa2 double 
knockout (DKO).  
We first tested if complete absence of AMPK signaling (in DKO MEFs) affected lysosomal 
morphology, by assessing lysosomal size using LAMP1-GFP (Fig. 5A). We observed that 
AMPK-DKO MEFs had a robust increase in the size of lysosomes. Next, we tested if the 
lysosomal pH was affected in AMPK-DKO MEFs using the dextran approach described 
above. The AMPK-DKO MEFs showed decreased lysosomal acidity, as assessed by the 
dextran approach (Fig. 5B). We then tested if lysosomal function was also impaired in 
AMPK-DKO, using the DQ-BSA assay. Indeed, there was a robust decrease in DQ-BSA 
degradation in the absence of AMPK signaling (Fig. 5C). Interestingly, the 2 catalytic 
subunits of AMPK, PRKAA1 and PRKAA2, seemed to be redundant for lysosomal function in 
these cells, because loss of either one, individually, had no effect in lysosomal proteolytic 
capacity (Fig. 5C). Notably, the decrease in lysosomal function in AMPK DKO could be 
rescued by treatment with the MCOLN1 activator MLSA1 (Fig. 5C). We further validated this 
result using the Magic Red assay, which also showed a robust decrease in lysosomal 
proteolytic activity in AMPK DKO cells, which was fully rescued by treatment with MLSA1 
(Fig. 5D). Altogether, these results support the idea that AMPK activity is an upstream 
regulator of the PIKFYVE-PtdIns(3,5)P2-MCOLN1 axis even in basal conditions, in the 
absence of mitochondrial defects. 
To confirm this possibility, we tested if the lysosomal Ca2+ levels were affected in AMPK DKO 
cells, using the GPN-Fluo4 approach described above. Most interestingly, AMPK DKO cells 
had increased lysosomal Ca2+, which could be rescued by treatment with the MCOLN1 
activator MLSA1 (Fig. 5E), in line with the result obtained for the proteolytic activity and with 
the results from the RC-kd cells (representative time lapse images in Video SV3). The pre-
treatment of the MEFs with xestospongin had no effect on the GPN-induced lysosomal Ca2+ 
release (data not shown). Overall, these data show that, in physiological conditions, AMPK 
activity is needed to regulate MCOLN1 and is thus required for proper lysosomal function. 
 
Reactivation of AMPK rescues lysosomal function  
Given that reactivation of AMPK in RC-kd cells rescued the levels of PtdIns(3,5)P2 (as shown 
above in Fig. 3D), we hypothesized that it may also rescue MCOLN1 function and 
consequently lysosomal enlargement. Indeed, treatment of RC-kd with the AMPK activator 
A769662 lead to normalization of lysosomal volume (Fig. 6A). Reciprocally, treatment of RC-
kd with dorsomorphine (also known as “compound C”), a routinely employed AMPK inhibitor 
[49], resulted in exacerbation of the lysosomal enlargement phenotype (Fig. 6A), suggesting 
that the activity of AMPK was inhibited but not completely ablated in RC-kd cells, in 
agreement with the western blot data on AMPK activity. AMPK activation is known to repress 
MTORC1 signaling [50]. Therefore, we tested if the repression of MTORC1 in RC-kd cells 
was sufficient to restore the lysosomal size. Treatment with RC-kd cells with the MTORC1-
specific inhibitor Torin1 resulted in exacerbation of the lysosomal enlargement phenotype 
(Fig S9), implying that the rescue of lysosomal size by AMPK activation in RC-kd cells 
cannot be attributed to the repression of MTORC1.  
Because AMPK activation in the RC-kd cells restored lysosomal size to normal, we next 
tested if lysosomal function was also improved. We showed earlier (see Fig. 1) that 
lysosomal impairment in RC-kds resulted in accumulation of autophagosomes. When we 
treated the RC-kd cells with the AMPK activator A769662, a clear decrease in 
autophagosomal LC3B-II was observed (Fig. 6B), denoting that the lysosomes are 
processing the autophagosomal cargo. It is important to note that AMPK is known to 
stimulate the formation of new autophagosomes, so the decrease in the levels of LC3B-II 
cannot be attributed to reduced autophagosome formation, but rather to increased lysosomal 
catabolic activity. Nevertheless, to objectively distinguish these 2 possibilities, we treated a 
batch of cells in each condition with chloroquine, which inhibits lysosomal degradation and 
thus demonstrably shows that the accumulation of autophagosomal cargo in RC-kd was 
caused by lysosomal impairment, and the resolution of the lysosomal malfunction restored 
autophagosome contents to control levels (Fig. 6B). Notably, the rescue of lysosomal 
function by AMPK required PIKFYVE, because simultaneous treatment with the AMPK 
activator A769662 and PIKFYVE inhibitor YM201636 was not able to resolve 
autophagosome accumulation (Fig. 6B). Therefore, it seems that the reactivation of the 
MCOLN1 channel was necessary to regain normal lysosomal function in RC-kd cells. 
Accordingly, treatment of RC-kd cells with the MCOLN1 activator MLSA1 also resolved the 
accumulation of autophagosomal mass (Fig. 6B). Importantly, reactivation of MCOLN1 also 
restored lysosomal acidification (Fig. S3A) as well as lysosomal proteolytic activity as 
assessed by Magic Red (Fig. S3B) and DQ-BSA assays (Fig. S3C), and normalized 
lysosomal size (Fig. 2F). 
 
Chronic reactivation of MCOLN1 in RC deficiency is beneficial 
To determine if the inhibition of lysosomal function in chronic RC deficiency is beneficial or 
detrimental to the cells, we subjected RC-kd and control cells to a mild death stimulus, using 
staurosporine, a cell death inducer [51]. Treatment of cells with staurosporine for 6-12 h 
induces mostly apoptotic cell death, but shorter treatments cause a mix of apoptosis and 
necrosis [52]. We treated the cells with 2 µM staurosporine for only 1 h, to create a mildly 
stressed environment rather than induce large-scale cell death. The cells were then labelled 
with ANXA5/annexin V (binds to phosphatidylserine exposed in the outer leaflet of the 
plasma membrane, a characteristic of apoptotic cells) and propidium iodide (accumulates in 
dead cells) (Fig. 7A). Under these conditions, we observed that the RC-kds presented a 2-
fold increase in apoptosis and in necrosis compared to the control cells (Fig. 7B). The 
treatment of the RC-kds with the MCOLN1 activator MLSA1 for 4 h had no significant effect 
on the apoptosis in RC-kds, but resulted in increased necrosis (Fig. 7A and quantification in 
7B).  
Importantly, we obtained similar results with ndufs4-/- MEFs, which had ~7-fold more necrotic 
cells than the WT MEFs, and there was a further increase in necrosis after MLSA1 treatment 
(Fig. 7C, quantified in 7D). Since the treatments with MLSA1, to reactivate MCOLN1, were 
carried out during 4 h in all experiments, including this cell death assessment, we tested 
longer periods of MLSA1 treatment to determine if the pro-death effect remained. Therefore, 
we treated scrambled and RC-kd cells for 24 h and 48 h with MLSA1, and assessed cell 
death using the propidium iodide assay (here only dead cells were scored, with no distinction 
between apoptosis and necrosis). We observed that while in the first 24 h the MLSA1 
treatment resulted in increased cell death, the effect in the period 24-48 h was opposite, with 
MLSA1 treatment in RC-kd resulting in decreased cell death. Thus, the reactivation of 
MCOLN1 under chronic mitochondrial RC deficiency seems to be a beneficial in the long run, 
despite the fact that it leads to increased cell death in the early hours of the treatment.  
  
DISCUSSION 
In this study, we identified the mechanism by which mitochondrial respiratory chain (RC) 
malfunction impairs lysosomal function and autophagy flux. Under chronic RC deficiency, 
FLCN expression is increased, causing a downregulation of AMPK signaling, which results in 
decreased PIKFYVE-dependent PtdIns(3,5)P2 levels (Fig. 8). PtdIns(3,5)P2 is needed to 
activate the MCOLN1 lysosomal Ca2+ channel, and therefore lower PtdIns(3,5)P2 levels 
result in lower MCOLN1 activity, and consequent accumulation of Ca2+ in the lysosome, 
lysosomal enlargement and impaired performance. The decrease in lysosomal activity is 
emphasized by the intralysosomal accumulation of undigested autophagosomal cargo. 
Remarkably, reactivation of MCOLN1, or of the whole pathway via AMPK activation, results 
in normalization of lysosomal function and resolution of the stalled autophagy.  
The effects of chronic mitochondrial deficiency on lysosomal function, mediated by a 
downregulation of AMPK and MCOLN1, sharply contrast with the effects of acute 
mitochondrial impairment. Under acute mitochondrial stress, both AMPK [13] and MCOLN1 
[53] are activated, as well as a AMPK-TFEB/MITF-dependent transcriptional program of 
lysosomal biogenesis. This program is repressed under chronic mitochondrial stress [13]. 
Accordingly, our RC-kds and ndufs4-/- cells were unable to trigger lysosomal biogenesis even 
under amino acid starvation, consistent with the known role of MCOLN1 in starvation-
induced activation of TFEB and other microphtalmia transcription factors. Overall, AMPK 
signaling seems to be the gatekeeper of lysosomal function under mitochondrial respiratory 
chain deficiency. Importantly, this occurs independently of MTORC1 signaling. Interestingly, 
we find that the cause of AMPK downregulation lies on the increased expression of FLCN, a 
tumor suppressor protein that inhibits both AMPK and TFEB. Accordingly, silencing FLCN in 
the cells with mitochondrial RC defects rescued most of the lysosomal phenotypes.  
The involvement of AMPK, a canonical responder to mitochondrial stress, in the regulation of 
lysosomal function via PIKFYVE-PtdIns(3,5)P2, both under basal conditions and under 
mitochondrial malfunction, raises the important point that AMPK is a signaling hub of the 
crosstalk between mitochondria and lysosomes. AMPK was already shown to regulate 
lysosomal biogenesis in cultured cells [13] as well as in vivo [12], but its role in the regulation 
of lysosomal function, at basal level, was unknown. While there is a large body of work on 
the role of AMPK in response to acute mitochondrial stress, less is known about the 
involvement of AMPK in chronic mitochondrial disease. Here, we observed that AMPK 
signaling is decreased in RC-kd cells but also downregulated in the brain of a mouse model 
of respiratory chain deficiency, ndufs4-/-. A decrease of AMPK activity in the brain would be of 
particular significance as many of the pathological consequences of impairments in the 
PIKFYVE-PtdIns(3,5)P2-MCOLN1 pathway are related to the nervous system [41, 54, 55].  
The decrease in the activity of this pathway has broad consequences for the lysosome and 
for the cells, given the importance of PtdIns(3,5)P2 for numerous cellular processes besides 
MCOLN1 regulation. The immediate consequence for the lysosome seems to be the loss of 
acidity and, consequently, function. Often, increase in lysosomal pH (loss of acidity) is 
associated with the inability to retain intralysosomal Ca2+. Here, we observe that 
accumulation of Ca2+ and lysosomal neutral pH occur simultaneously. These results are in 
agreement with data showing increased (less acidic) pH in MCOLN1-deficient cells [24], and 
with data showing that lysosomal Ca2+ refilling is independent of the pH gradient [56].  
The broader biological relevance of the pathway here described is underscored by the 
embryonic lethality of constitutive pikfyve knockout in mouse [44], neonatal lethality of mice 
lacking VAC14 [57], and profound neurodegeneration in a mouse with a mutation in FIG4 
[58], 2 proteins associated with PIKFYVE and necessary for its activity. At the cellular level, 
defects in PtdIns(3,5)P2 homeostasis affect lysosomal function and trafficking, endosomal 
sorting, and retrograde traffic from the lysosome to the Golgi complex [41]. At the organismal 
level, defects in PtdIns(3,5)P2 are associated with several human diseases, thus raising the 
possibility that lower activity of the PIKFYVE-PtdIns(3,5)P2-MCOLN1 pathway may have a 
role in the pathology of mitochondrial diseases. Interestingly, activation of AMPK activity was 
found to be beneficial in a mouse model of myopathy caused by defects in mitochondria RC 
complex IV [59]. It is important to note that while this study did not determine the mechanism 
by which AMPK activates PIKFYVE, we have established a direct interaction between the 
two proteins, and showed that reactivation of AMPK in RC-kd is dependent on PIKFYVE 
activity. 
Furthermore, MCOLN1 also regulates lysosomal exocytosis [60], which seems to have a 
biphasic response to oxidative stress: increased by short-term bursts, but inhibited by 
prolonged oxidative stress, both in a MCOLN1-dependent manner [60]. When placing our 
results in this context, it could be speculated that under chronic mitochondrial malfunction it 
is beneficial to suppress lysosomal exocytosis in order to avoid depleting the cells of 
constituents. Furthermore, when considering tissues, in vivo, persistent lysosomal exocytosis 
would likely result in permanent inflammation [61]. Our observation that restoration of 
lysosomal function leads to increased cell death in cells with chronic mitochondrial 
impairment suggests that inhibition of the lysosome is a protective mechanism, at least under 
basal culture conditions and for a short 4-h treatment with the MCOLN1 activator MLSA1. 
However, longer treatment with MLSA1 decreased cell death, suggesting that in the long 
term MCOLN1 reactivation in chronic mitochondrial malfunction may be beneficial. It is 
possible that the early increase in cell death upon the 4-h treatment with MLSA1 is due to 
increase of cytoplasmic Ca2+ in RC-kd cells that were already adapted to lower cytoplasmic 
Ca2+ levels. Indeed, necrotic cell death is associated with cytoplasmic Ca2+ overload [62]. 
The inhibition of lysosomal function comes, evidently, at a cost. The lysosomes are an 
important metabolic hub, with roles in amino acid sensing and coordination, as well as a 
major signaling node which regulates many aspects of cell life [25]. By repressing lysosomal 
function, the cells create a new set of problems akin to that observed in lysosomal storage 
diseases which, like mitochondrial diseases, often have devastating consequences for the 
central nervous system, cardiac function and skeletal muscle [63]. Interestingly, the MCOLN1 
knockout mice present several phenotypes that are often observed in mitochondrial 
diseases, including reduced myelination [54], neurological perturbations [64] and retinal 
degeneration [55]. While it is a speculative statement at this point, it is possible that the 
MCOLN1 inhibition is contributing to the pathological phenotypes observed in mouse models 
and patients with mitochondrial diseases.  
The interplay here described between mitochondria and lysosomes brings the issue of 
organelle cross-talk to center stage. While defects in cellular organelles were studied in an 
organelle-specific manner, it is now clear that to fully understand the impact of one 
dysfunctional organelle, such as the mitochondria, it is pivotal to understand how the other 
cellular organelles respond to the mitochondrial defect [13, 65-69]. This is particularly 
relevant since the existence of contact sites between mitochondria and lysosomes was 
recently reported in mammalian cells [70]. Further studies will elucidate if the crosstalk 
between mitochondria and lysosomes unveiled in the present study is dependent on these 
contact sites, or if it can affect their occurrence [71-73]. The interplay between these 
organelles and the endoplasmic reticulum is also a key question to be addressed, particularly 
given that the lysosomal Ca2+ contents are refilled by the endoplasmic reticulum [56].  
The mechanisms that mediate the crosstalk between mitochondria and lysosomes remain 
unexplored, regardless of their involvement in contact sites or via signaling pathways. This 
question goes beyond fundamental biology, since in many diseases caused by primary 
malfunction of one organelle (e.g., mitochondrial diseases, lysosomal storage diseases, etc.), 
defects in other organelles have been extensively reported [65]. However, it is usually 
assumed that the secondary perturbations in other organelles occur chaotically and 
progressively, as eventually every component of a diseased cell would cease to function. Our 
data suggests that impairment of lysosomes in mitochondrial disease is not a chaotic 
succession of events, but rather a highly regulated process. The understanding of this 
process will aid in the identification of targets for novel therapeutic strategies, which will be of 
relevance not just for mitochondrial and lysosomal diseases but also to several 
neurodegenerative syndromes that present defects in both organelles. 
  
MATERIALS AND METHODS 
Cell culture and generation of stable knockdown cells 
HeLa cells and MEFs were grown in DMEM high glucose medium (Gibco, 11965) 
supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin at 37°C and 5% 
CO2. ndufs4
-/- MEFs were prepared as described previously [74]. AMPK MEFs [75] prkaa1-/-, 
prkaa2-/-, and prkaa1-/- prkaa2-/- and corresponding wild type, were a kind gift by Dr. Benoit 
Viollet (Institut Cochin, Paris, France). All MEFs were immortalized using E6E7 viral particles 
as previously described [74]. 
Lentiviral stable knockdown generation was done by growing HEK293T packaging cells in 
DMEM high glucose supplemented with 10% FBS and after 24 h were transfected with viral 
components and shRNA against target genes (or scrambled control) using Lipofectamine 2000 
(Invitrogen, 11668-019), grown and concentrated using Lenti-X Concentrator (Clontech 
Laboratory, 631232) according to the manufacturer’s instructions. The shRNA constructs were 
purchased from Open Biosystems (Dharmacon). HeLa cells were then seeded at 12000 
cells/cm2 and grown overnight to 70-80% confluence. These cells were transduced with the 
lentiviral particles using Polybrene (8 µg/ul; Sigma-Aldrich TR-1003-G). Puromycin (Fisher 
Scientific, BP2956-100; 6 mg/ml) was used as selection agent. 
Transient Atg5 and FLCN knockdowns were done with siRNA (RNAi DsiRNA Duplex Oligos 
from IDT) and Fugene 6 Transfection Reagent (Promega, E2691) according to the 
manufacturer’s instructions.  
The LAMP1-GFP (LAMP1-mGFP; 34831) [76], GFP-LC3 (pEGFP-LC3; 24920) [77] and RFP-
LC3 (pmRFP-LC3; 21075) [78] were obtained from Addgene (deposited by Dr. Esteban 
Dell'Angelica, Dr. Toren Finkel and Dr. Tamotsu Yoshimori, respectively).  
 
Drugs and cellular treatments 
The following drugs were used: A769662 (InvivoGen, inh-a769) and dorsomorphin (compound 
C; Sigma Aldrich, P5499); Torin1 (BioVision, 2273); MLSA1 (Sigma-Aldrich, SML0627) and 
YM201636 (InvivoGen, inh-ym20); staurosporine (Sigma-Aldrich, 37095). These compounds 
were solubilized in DMSO (Sigma-Aldrich, D8418), which was used as vehicle control. 
Mitochondrial uncoupler FCCP (Sigma- Aldrich, C2920) or respiratory chain inhibitor antimycin 
A (Sigma-Aldrich, A8674) were solubilized in ethanol (Sigma-Aldrich, 51976), which was used 
as vehicle control for the experiments involving these drugs.  
 
Western blotting 
Whole-cell extracts of cultured human cells were prepared in 1.5% n-dodecylmaltoside (Carl 
Roth, CN26.2) in PBS (Sigma-Aldrich, P44177) as described previously [68]. Briefly, gels were 
loaded with 50 µg of total protein per well, proteins were separated in 12% SDS-PAGE gels 
and transferred to polyvinylidene fluoride (PVDF) membranes (Amersham Life Technologies, 
GE10600023). The following antibodies were used for immunoblotting: UQCRC1 (Abcam, 
ab110252), GAPDH (Sigma-Aldrich, G9545), HPRT (Abcam, ab10479), LAMP1 
(Developmental Hybridoma Bank, H4A3) for mouse; (Abcam, ab24170) samples) for human 
samples, LC3B (Cell Signaling Technology, 3868), AMPKα1 (Cell Signaling Technology, 
2795), p-PRKAA1/AMPKα1 (T172) (Cell Signaling Technology, 2535), FLCN (Cell Signaling 
Technology, 3697), FNIP1 (Abcam, ab134969), TSC2 (Cell Signaling Technology, 4308), p-
TSC2 (S1387) (Cell Signaling Technology, 5584), PIKFYVE (Proteintech, 13361-1-AP), 
ACAC/ACC (Cell Signaling Technology, 3676), p-ACAC/ACC (Ser79) (Cell Signaling 
Technology, 3661), RPS6/S6 (Cell Signaling Technology, 2217S), p-RPS6/S6 (Cell Signaling 
Technology, 4858S), MCOLN1 (Novus, NBP1-92152). Band density quantification was 
determined using ImageJ after subtraction of background, and normalized against loading 
controls (HPRT, GAPDH, RPL7). 
 
Immunoprecipitations and western blot analyses 
To evaluate the interaction between AMPK and PIKFYVE, scrambled control and RC-kd HeLa 
cells were harvested in cold PBS on ice by scraping. Lysates were prepared from cell pellets 
using WCE buffer (40 mM Tris-HCl, pH 7.5 [Carl Roth, 9090.2], 150 mM NaCl [AppliChem, 
A1430,0010], 1 mM EDTA, 10 mM MgCl2 [VWR, 8.14733.0100] supplemented with 1x HALT 
protease and phosphatase inhibitor cocktail [Thermo Scientific, 78442]). Cell lysates were 
incubated at 40°C with rotation for 20 min and centrifuged at 16000 x g for 20 min. The 
supernatants were collected and protein concentrations were determined by the Bradford 
assay. 500 µg of protein was incubated with either anti PRKAA (Cell Signaling Technologies, 
5832) (1:100) or with IgG (1:100; Dianova, 111-001-008) and 30 µL each of equilibrated protein 
G agarose beads (Millipore, 16-266) overnight at 4 °C with rotation. Beads were then washed 
4 times in WCE buffer and boiled in Laemmli buffer containing β-mercaptoethanol (Carl Roth, 
4227.3) for 5 min at 95°C and centrifuged at 16000x g for 1 min. Gels were loaded with 10 µL 
of the supernatants and subjected to western blotting as described and probed with anti-
PRKAA, anti-PYKFYVE and anti-GAPDH antibodies. 
 
Quantitative RT-PCR 
RNA extraction and purification were performed as described previously [13]. cDNA was 
diluted 1:100, and each 8 µl reaction contained 4 µl diluted cDNA, 0,2 µl dilutions of each 
primer (from 25 µM stock), and 3.6 µl iTaq Universal SYBR Green Supermix (Bio-Rad, 
1725120). The data were analyzed by the ΔΔCT method, using HPRT or GAPDH as control 
gene. 
 
DQ-BSA 
Lysosomal protease activity in cells was measured using DQ™ Green BSA (Life Technologies, 
D12050) or DQ™ Red BSA (Life Technologies, D12051). The cells were plated at a density of 
12.000 cells/well in a black, clear bottom 96 well-plate, 24 hours before. The medium was 
replaced with DMEM high glucose containing 10 µg/ml DQ Green BSA and incubated 1 h at 
37°C. After the incubation the plate was washed twice with PBS and the medium was replaced 
with 100 µl of EBSS medium.  Lyosomal protease activity was measured as fluorescence in a 
microplate reader (BioTek) at 495 nm excitation, 525 nm emmision each 5 min for 4 h. The 
slope of the linear range (0-90 minutes of EBSS) was used for analysis. 
 
Magic Red 
Cells were plated in 24-mm round coated glass coverlips (Marienfeld, 0101060) the day before 
the experiment. The incubation of the cells with Magic Red (Bio-Rad, ICT937) took 20 min, 
after which the coverslip was washed in warm imaging buffer and then placed on a coverslip 
holder filled with pre-heated imaging buffer. The coverslip was then immediately taken to the 
Nikon/PerkinElmer Spinning Disk microscope under a humidified chamber heated at 30°C, and 
imaged. Data was analyzed using ImageJ. 
 
Electron Microscopy 
Cells seeded on 24-mm glass coverslips were fixed with 2.5% (vol:vol) glutaraldehyde in 0.1 
M sodium cacodylate during 1 h at room temperature. After washing with 0.1 M cacodylate 
buffer, cells were post-fixed with 1% OsO4 solution and 1.5% ferrocyanide in 0.1 M cacodylate 
during 1 h at room temperature. The samples were then washed 3 times in 0.1 M cacodylate 
buffer following 3 times in Millipore water and then incubated in 1% aqueous uranyl acetate at 
4°C overnight. Then, cells were rinsed with Millipore water, dehydrated with ethanol and 
infiltrated in Epon (CarlRoth, 8619.1) using 1:1 (v:v) resin and anhydrous ethanol for 1 h. 
Additionally, 2 steps of 100% resin during 1 h were performed. After, the cells were incubated 
at 45°C over night following a second over night at 60°C. Thin sections were prepared and 
imaged using a LEO 912AB transmission electron microscope with Omega energy filter 
operated at 120 kV. 
 
Flow Cytometry 
Cells were incubated with MitoSOX (Life Technologies, M36008) 50 nm for 20 min at 37°C; 
Fluo-4-AM (Life Technologies, F14201) 2 µM for 20 min at 37°C; LysoTracker Green DND-26 
(Life Technologies, L7526) 200 nM for 20 min at 37°C under regular cell culture conditions. 
Then, they were washed 3x in warm PBS, detached with trypsin, washed and ressuspended 
in PBS and sorted using a FACScan (BD Biotechnology). 
 
Microscopy 
Cells were plated using coverslips on 12-well plates and transiently transfected with GFP-LC3, 
RFP-LC3, LAMP1-GFP (all obtained from Addgene, described in detail in the construct 
section), PtdIns(3,5)P2 GFP probe [42], lysosomal Ca2+ probe using Fugene 6 Transfection 
Reagent (Promega, E2691) according to the manufacturer’s instructions. Images were 
obtained using a Nikon/PerkinElmer Spinning Disk microscope or with a Zeiss LSM 880 Laser 
Scanning Microscope with Airyscan. Data was analyzed using Imaris 8.1.1 (Bitplane) and 
ImageJ software. 
 
Acridine orange assay 
Scrambled or RC-kds HeLa cells were seeded at 10000cells/cm2 in coated coverslips. On the 
following day, the cells were preloaded for 20 min with 10 μg/ml acridine orange (Sigma-
Aldrich, 318337), followed by 3 fast washes and 3 5-min washes in pre-warmed (37°C) imaging 
buffer, and then moved to the spinning disc microscope for imaging. The cells were imaged in 
time lapse to capture the green and red channels. Photodamage was induced by continuous 
illumination between images at 488 nm. The data were analyzed as previously described33. 
 
Lysosomal Ca2+ assessment 
The experiment was performed as described previously [69]. Briefly, the cells were plated on 
24-mm glass coverslips at a density of 5,000 cells/cm2 the day before the experiment. On the 
day of the experiment, each coverslip was labelled with 2 µM Fluo-4-AM for 20 min at 37̊°C. 
The coverslip was then rinsed 3 times in PBS pre-warmed to 37̊C, further washed 3x5 min in 
warm PBS, placed in the coverslip holder, and incubated with warm Ca2+-free imaging buffer. 
The coverslip was then placed in a Nikon/PerkinElmer Spinning Disk microscope, kept in a 
humidified 5% CO2 chamber, warmed to 30°C. Images were taken with a 40x objective, at the 
rate of 3 frames per second. One min after the image collection started, we added glycyl-L-
phenylalanine 2-naphthylamide (GPN) (Sigma-Aldrich, P5891) to a final concentration of 50 
µM and followed fluorescence in the green channel for an additional 3 min. The data were then 
analyzed using ImageJ to determine the ratio between the intensity of each image compared 
to the first frame, which was used to calculate the difference between the peak cytoplasmic 
fluorescence intensity (obtained after GPN addition) and the baseline established before GPN 
was added. 
 
ndufs4-/- tissue samples preparation 
All ethical regulations regarding animal handling and maintenance were followed. The mice 
were analyzed at 3 and 6 weeks of age (their lifespan is 7 weeks). The brains were collected 
for RNA and protein analysis, as described [74]. The samples were lysed in RIPA buffer 
(prepared as described previously [69]) with protease and phosphatase inhibitor cocktail 
(Thermo Scientific, 78430). Quantitative PCR was performed on RNA purified from these same 
mouse tissues using Crystal RNA mini Kit (Biolab, 31-010-404) using the same method already 
described for human cells, but with mouse-specific primers.  
 
Statistical analyses 
For western blotting, flow cytometry, quantitative RT-PCR, DQ-BSA, all data points represent 
the mean of at least 2, but often 3 independent biological replicates. Error bars represent 
standard deviation unless otherwise stated. For images, typically at least 40 cells were 
analyzed from at least 2 independent experiments (unless otherwise stated); the data indicate 
average and the error bars represent the standard error of the mean. For pairwise 
comparisons, P-values were determined using unicaudal Student´s t test, otherwise one-sided 
ANOVA was employed.  
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Figure Legends 
 
Figure 1. Respiratory chain deficiency causes lysosomal enlargement independently of 
autophagy. (A) Increase in the number of GFP-LC3-positive structures in the RC-kd cells. 
Representative equatorial (through the middle of the cell) plane confocal images show 
autophagosome distribution (by expression of the autophagosomal marker GFP-LC3) in 
HeLa cells with scrambled control (upper panel), or stable knock-down of the respiratory 
chain subunit UQCRC1 (RC-kd1 and RC-kd2, lower panel). Scale bar: 2 μm. The 
quantification of average lysosomal area is presented in the plot in the upper right panel as 
average ± s.e.m.(s.e.m), (scrambled N=54 cells; RC-kd1 N=60 cells; RC-kd2 N=54 cells; 
from three independent experiments). ANOVA adjusted p-value *p<0.05 **p<0.001. (B) 
Western blot analysis of whole-cell extracts for LC3B in RC-kd and scrambled control HeLa 
cells, using GAPDH as loading control. The band for LC3B-II, a marker of autophagosomal 
mass, is increased in RC-kds. Column plot shows average plus standard deviation of at least 
three independent experiments, with duplicates in each experiment. ANOVA p-value 
*p<0.05. (C) Autophagosomes remain undigested in the RC-kd cells. Representative 
spinning disk confocal images of autophagosome and lysosomes, by co-expression of the 
lysosomal marker LAMP1-GFP and of the autophagosomal marker RFP-LC3 in scrambled 
control or RC-kd HeLa cells, or HeLa cells treated with chloroquine, as a positive control for 
impaired lysosomal function. Scale bar: 0.5 μm. The insets on the right side show the 
magnification of the areas inside the squares. (D) Lysosomal volume is increased in the RC-
kd cells. Representative confocal microscopy images of HeLa cells (scrambled, upper panel; 
or RC-kds, bottom panel) stained with anti-LAMP1 antibody (secondary conjugated with 
Alexa-488 fluorophore). Scale bar: 2 μm. The box plot on the upper right panel shows the 
distribution of the lysosomal volume across at least 50 cells obtained for each condition, 
obtained from three independent experiments, and also indicates the average volume and 
the standard deviation. T-test p-value **p<0.005. The histogram on the lower right panel 
indicates the frequency distribution of lysosomal size in the control and RC-kd cells, showing 
that the RC-kds have less small lysosomes (<5 nm3) and a robust increase in the amount of 
very large lysosomes (>15 nm3). (E) Saturated lysosomes are detected in RC-kds. 
Representative electron micrographs showing the presence of electron-dense (saturated) 
lysosomes in RC-kd cells, which are rarely observed in control cells. Scale bar: 500 nm. The 
box plot on the upper right panel shows the distribution of the lysosomal volume across at 
least 12 cells obtained for each condition, obtained from 3 independent experiments, and 
also indicates the average volume and the standard deviation. T-test p-value *p<0.05. The 
histogram on the lower right panel indicates the frequency distribution of lysosomal size in 
the control and RC-kd cells, showing that the RC-kds have less small lysosomes and an 
increase in the amount of very large lysosomes. (F) Lysosomal enlargement in RC-kds is not 
caused by excessive autophagosome trafficking. Representative confocal microscopy 
images of HeLa cells (scrambled, upper panel; or RC-kds, bottom panel), transfected with 
siRNA against ATG5 or a scrambled sequence (siRNA control), stained with anti-LAMP1 
antibody (secondary conjugated with Alexa Fluor 488 fluorophore). Scale bar: 2 μm. The plot 
on the right panel shows the average ± s.e.m. lysosomal volume across at least 40 cells 
obtained for each condition, obtained from 2 independent experiments. ANOVA p-value 
**p<0.01. The histogram on the bottom panel indicates the frequency distribution of 
lysosomal size in the control and RC-kd cells, showing that the silencing of ATG5 caused an 
increase in the number of larger lysosomes both in scrambled and RC-kd HeLa cells.  
Figure 2. Respiratory chain deficiency causes impaired lysosomal function and accumulation 
of lysosomal Ca2+. (A) Lysosomal acidification is impaired in RC-kd. Representative 
equatorial plane confocal images of RC-kd and scrambled control HeLa cells stained with 
dextran-Oregon Green and dextran-TMRM. Scale bar: 2 μm. Dextran-Oregon Green is 
quenched under acidic pH, so increased green:red ratio denotes impaired lysosomal 
acidification. The average ± s.e.m. green:red ratio for at least 40 cells in 3 independent 
experiments is presented in the plot on the right panel (normalized to scrambled 
green/red=1). (B) Decreased lysosomal proteolytic capacity in RC-kd. DQ-BSA is bovine 
serum albumin labelled with a green fluorophore. It is taken up by endocytosis, and delivered 
to the lysosomes. As a monomer, the fluorophore is too concentrated and the signal is 
quenched. As DQ-BSA is degraded by the lysosomal proteases, it releases monomers which 
emit fluorescence. This process is illustrated in the figure. The rate of DQ-BSA hydrolysis 
(increase of fluorescence units per min, per mg of protein) is a function of lysosomal 
proteases, and was measured using a plate reader over 2 h. The linear range was used to 
determine the rate. The average ± s.e.m. rate for each condition (20 wells in a 96-well plate) 
is presented in the plot on the upper right panel. These values are a representative 
experiment. Three independent experiments were performed, with at least 20 wells per 
condition. ANOVA p-value *p<0.05 ***p<0.001. (C) Increased lysosomal Ca2+ levels in RC-
kds. Cells are loaded with the lysosomotropic compound Gly-Phe β-naphthylamide (GPN), 
which readily diffuses throughout the cell. When entering the lysosome, GPN is activated by 
CTSC, and the activated product forms pores in the lysosomal membrane which allow the 
release of lysosomal contents to the cytoplasm, including Ca2+. The increase in cytoplasmic 
Ca2+ upon GPN treatment is measured by changes in the fluorescence intensity of the 
cytoplasmic Ca2+ indicator Fluo-4 over time. The process is illustrated in the upper panel. The 
curves obtained for Fluo-4 fluorescence intensity over time scrambled and RC-kds cells are 
presented in the bottom panel (average of at least 32 cells per condition, in 3 independent 
experiments), normalized to the fluorescence intensity in the first frame. The increased 
magnitude of the peaks are a function of increased lysosomal Ca2+contents in RC-kds. The 
Fluo-4 intensity curves in the presence of ITPR/IP3R inhibitor xestospongin C are presented 
as dotted lines (here, average of 30 cells from 2 independent experiments is shown). (D) 
Quantification of the peak height in the GPN-induced release of lysosomal Ca2+ to cytoplasm, 
as an estimation of lysosomal Ca2+ contents. In the plot, the scrambled and RC-kds (RC-kd1 
and RC-kd2) are shown (average ± s.e.m. of at least 29 cells per condition in 3 independent 
experiments) both under basal conditions and after treatment with MLSA1 20 µM for 4 h, 
prior to the GPN experiment. MLSA1 is an activator of MCOLN1, one lysosomal Ca2+ 
channel. The RC-kds have increased lysosomal Ca2+, which is normalized when the cells are 
treated with the activator of MCOLN1. ANOVA p-value *p<0.05 ***p<0.001; n.s. (E) Protein 
levels of MCOLN1 are not changed in RC-kd. Representative western blot of whole-cell 
extracts for MCOLN1 in RC-kd and scrambled control HeLa cells, in duplicate, using GAPDH 
as loading control. Column plot shows average plus standard deviation of at least 2 
independent experiments, with duplicates in each experiment. T-test yielded a p-value>0.05 
(non-significant, n.s.). (F) Lysosomal enlargement in RC-kd is rescued by reactivation of 
MCOLN1. Representative equatorial plane confocal images of HeLa cells (scrambled, upper 
panel; or RC-kds, bottom panel), treated with the MCOLN1 activator MLSA1 20 µM 4 h (or 
DMSO as vehicle control), stained with anti-LAMP1 antibody (secondary conjugated with 
Alexa Fluor 488 fluorophore). Scale bar: 2 μm. The plot on the right panel shows the average 
± s.e.m. lysosomal volume across at least 45 cells obtained for each condition, obtained from 
3 independent experiments. ANOVA p-value *p<0.05,**p<0.005. (G) Cytoplasmic Ca2+ levels 
are decreased in RC-kd, and return to control values upon MCOLN1 reactivation. 
Cytoplasmic Ca2+ levels were assessed using the cytoplasmic indicator Fluo-4, by flow 
cytometry in scrambled, RC-kd cells treated with MCOLN1 activator MLSA1 20 µM 4 h (or 
DMSO as vehicle control). The average distribution of cells per fluorescence intensity is 
plotted on the left panel. The quantification of the average ± st.dev of at least 3 independent 
replicates (repeated twice, representative experiment plotted) per condition is presented in 
the bar graph. ANOVA p-value *p<0.05, ***p<0.001. 
Figure 3. AMPK signaling is downregulated in RC-kd. (A) Schematic representation of the 
pathway presumably linking AMPK with MCOLN1 activity. (B) Western blot analysis of 
whole-cell extracts (first 2 lanes) as well as extracts obtained from AMPK 
immunoprecipitation, using a pan-antibody against PRKAA1 and PRKAA2. Lanes 3-4 show 
two independent experiments of AMPK immunoprecipitate in control cells, and lanes 5-6 
show 2 independent experiments of AMPK immunoprecipitate in RC-kd cells. Lanes 7-8 
show the unbound eluate, and lane 9 is the negative control. The proteins detected include 
AMPK and PIKFYVE, which is readily detected in the AMPK immunoprecipitate. GAPDH is 
detected in the input samples and in the unbound eluate, but not in the AMPK 
immunoprecipitate, demonstrating specificity of the interaction between AMPK-PIKFYVE. (C) 
Decreased phosphorylation of AMPK targets in RC-kd. Western blot analysis of whole-cell 
extracts for UQCRC1, AMPK, p-AMPK (T172), TSC2. p-TSC2 (S1387) and PIKFYVE in RC-
kd and scrambled control HeLa cells, using GAPDH as loading control. The bands for 
UQCRC1, p-AMPK and p-TSC2 are decreased in RC-kds, while there is no change in 
PIKFYVE protein amount, as shown in the plots on the right side. Column plot shows 
average±s.d. of 3 independent experiments, with duplicates in each experiment. T-test p-
value *p<0.05 (D) Decreased PtdIns(3,5)P2 levels in the lysosomes of RC-kd cells, returned 
to control levels by reactivation of AMPK. Representative equatorial plane confocal images of 
HeLa cells (scrambled with vehicle control DMSO; scrambled with PIKFYVE inhibitor 
YM201636 1 μM 4 h; RC-kds with vehicle control DMSO; RC-kd treated with AMPK activator 
A769662 100 μM 4 h), cotransfected with ML1N*2-GFP and LAMP1-RFP. The localization of 
the ML1N*2-GFP probe to the lysosome is related to the lysosomal PtdIns(3,5)P2 content. 
Scale bar: 2 μm. The plot presents the quantification of PtdIns(3,5)P2 fluorescence on 
microscopy images of HeLa, scrambled and RC-kd, cotransfected with ML1N*2-GFP and 
LAMP1-RFP. Control cells were also treated with the PIKFYVE inhibitor YM201636 1 μM 4 h, 
and RC-kd were treated with AMPK activator A769662 100 μM 4 h (or DMSO as vehicle 
control). The plot shows the average±s.e.m ML1N*2-GFP intensity on the spots marked with 
LAMP1-RFP, across 45 cells for each condition, obtained from 3 independent experiments. 
ANOVA p-value **p<0.005; ***p<0.001; n.s., non-significant. 
Figure 4. FLCN represses AMPK signaling in RC-kd cells. (A) Western blot analysis of 
whole-cell extracts for FLCN and FNIP1 in RC-kd and scrambled control HeLa cells, using 
GAPDH as loading control. Both proteins are more abundant in RC-kds. Column plot shows 
average plus standard deviation of 2 independent experiments, with duplicates in each 
experiment. ANOVA p-value *p<0.05. (B) Transcript levels of FLCN, FNIP1 and FNIP2 
measured by quantitative RT-PCR, in control and RC-kd cells, calculated by the ΔΔCt 
method using GAPDH as a control gene. Column plot shows average plus standard 
deviation of at least 3 independent experiments, with duplicates in each experiment. T-test p-
value ***p<0.001. (C) Western blot analysis of control and RC-kd whole-cell extracts with 
FLCN silencing (siRNA FLCN) or with control siRNA (siRNA ctrl), using GAPDH and HPRT 
as loading controls. Decrease of FLCN leads to the reactivation of AMPK signaling. Column 
plot shows average plus standard deviation of 2 independent experiments. T-test p-value 
*p<0.05, **p<0.01 against basal condition (scrambled+siRNA ctrl). (D) FLCN silencing in RC-
kd cells normalizes lysosomal volume. Representative equatorial plane confocal images of 
HeLa cells (scrambled, left side; or RC-kds, right side), with FLCN silencing (bottom panel) or 
control siRNA (upper panel), stained with anti-LAMP1 antibody (secondary conjugated with 
Alexa Fluor 488 fluorophore). Scale bar: 5 μm. The column plot on the upper right panel 
shows the average±st.d. of the lysosomal volume across 30 cells acquired for each 
condition, obtained from 2 independent experiments. ANOVA p-value **p<0.05, ***p<0.001 
(E) FLCN silencing restores lysosomal acidification in RC-kd. Representative spinning-disk 
microscopy images of RC-kd and scrambled control HeLa cells, with FLCN siRNA or 
scrambled control siRNA, stained with dextran-Oregon Green and dextran-TMRM. Scale bar: 
5 μm. Dextran-Oregon Green is quenched under acidic pH, so increased green:red ratio 
denotes impaired lysosomal acidification. The average ± st.d green:red ratio for 30 cells from 
2 independent experiments is presented in the plot on the right panel (normalized to 
scrambled green:red=1). ANOVA p-value ***p<0.001 
Figure 5. Impaired lysosomal function in AMPK-deficient cells. (A) Increased lysosomal 
volume in cells lacking AMPK activity (prkaa1 prkaa2 double-knockout MEFs, AMPK DKO). 
Representative equatorial plane confocal images of mouse embryonic fibroblasts derived 
from WT (upper panel) or AMPK DKO (lower panel) mice, transfected with LAMP1-GFP. 
Scale bar: 2 μm. The column plot on the right shows the average±st.d. of the lysosomal 
volume across at least 60 cells acquired for each condition, from 2 independent experiments. 
T-test p-value *p<0.05 (B) Equatorial plane confocal images of AMPK DKO and WT MEF 
cells stained with dextran-Oregon Green and dextran-TMRM. Scale bar: 3 μm. Dextran-
Oregon Green is quenched under acidic pH, so increased green:red ratio denotes impaired 
lysosomal acidification. The average ± s.e.m. green:red ratio for 40 cells from 2 independent 
experiments is presented in the plot on the right panel (normalized to WT green:red=1). (C) 
Decreased lysosomal proteolytic capacity in AMPK DKO MEFs, which was rescued after 
reactivation of the lysosomal Ca2+ channel MCOLN1. The rate of DQ-BSA hydrolysis 
(increase of fluorescence units per min, per mg of protein) is a function of lysosomal 
proteases, and was measured using a plate reader over 2 h. The linear range was used to 
determine the rate. The average±st.d. rate for each condition (20 wells in a 96-well plate) is 
presented in the plot on the upper right panel. These values are a representative experiment. 
Three independent experiments were performed, with 20 wells per condition. ANOVA p-
value *p<0.05; n.s., non-significant. (D) Decreased activation of Magic Red dye in AMPK 
DKO MEFs. Magic Red freely diffuses through the cell, and upon activation in the lysosomes, 
it emits red fluorescence proportional to the activity of lysosomal CTSB. The AMPK DKO 
cells present a sharp decrease in the activation of Magic Red, which is normalized by 
treatment with the MCOLN1 activator MLSA1 20 µM 4 h (DMSO as vehicle control). The 
column plot shows the average±st.d. intensity of Magic Red signaling from 40 cells per 
condition from 2 independent experiments. ANOVA p-value ***p<0.001 (E) Increased 
lysosomal Ca2+ in AMPK DKO MEFs. Cells are loaded with the lysosomotropic compound 
Gly-Phe β-naphthylamide (GPN), which readily diffuses across the cell. When entering the 
lysosome, GPN is activated by CTSC, and the activated product forms pores in the 
lysosomal membrane which allow the release of lysosomal contents to the cytoplasm, 
including Ca2+. The increase in cytoplasmic Ca2+ upon GPN treatment is measured by 
changes in the fluorescence intensity of the cytoplasmic Ca2+ indicator Fluo-4 over time. The 
curves obtained for Fluo-4 fluorescence intensity over time scrambled and RC-kds cells are 
presented in the bottom panel (average of at least 30 cells per condition; 2 independent 
experiments were performed), normalized to the fluorescence intensity in the first frame. The 
increased magnitude of the peaks are a function of increased lysosomal Ca2+contents in 
AMPK DKO, and the average±st.d. of the peaks are presented in the column plot below. 
ANOVA p-value *p<0.05 
Figure 6. AMPK activation rescues lysosomal size. (A) Lysosomal enlargement in RC-kd 
cells is rescued by AMPK reactivation. Representative Airyscan confocal equatorial plane 
images of scrambled or RC-kd HeLa cells, treated with A769662 or compound C (DMSO as 
vehicle control), and stained with anti-LAMP1 antibody (secondary conjugated with Alexa 
Fluor 488 fluorophore). Scale bar: 3 μm. The measurement of the lysosomal volume across 
at least 40 cells obtained for each condition from 2 independent experiments, is plotted on 
the right panel as average±s.e.m.. ANOVA p-value *p<0.05, **p<0.005 and ***p<0.001. (B) 
Reactivation of AMPK signaling in RC-kd restores autophagosome digestion. Western blot 
analysis of whole-cell extracts for LC3B in RC-kd and scrambled control HeLa cells, using 
GAPDH as loading control. Every condition was also subject to the treatment with the 
lysosomal inhibitor chloroquine, to assess the amount of autophagosomes that accumulate 
specifically due to lysosomal impairment. The band for LC3B-II, a marker of autophagosomal 
mass, is increased in RC-kds and rescued by activation of AMPK. This rescue is dependent 
on the activity of PIKFYVE (inhibited by YM201636). Column plot shows average±s.d. of 2 
experiments. ANOVA p-value *p<0.05 (against control condition in the absence of 
chloroquine, lane 1). 
Figure 7. Cell death in RC-kd and ndufs4-/-. (A) Apoptosis and necrosis evaluation in 
scrambled, RC-kd and RC-kd HeLa treated with 20 μM ML-SA1 for 4 h. The cells were 
subject to 2 µM staurosporine for 1 h prior to collection as a mild cell death-inducing 
condition. Afterwards the cells were labelled with ANXA5/annexin V (a marker of apoptotic 
cell death that recognizes externalization of phosphatidylserine to the outer leaflet of the 
plasma membrane) and propidium iodide (accumulates in dead cells). Fluorescence was 
measured by flow cytometry; the experiment was done in triplicate. (B) Column plot showing 
that that RC-kd cells present more apoptosis and necrosis than the scrambled cells. 
Additionally, MLSA1 treatment has no effect in the apoptotic cells but significant increases 
the necrotic cells. The plot shows variation in the number of cells undergoing death under 
each condition compared to the control (fold change; scrambled=1). ANOVA p-value 
*p<0.05, **p<0.005, ***p<0.005 (C) Measurement of apoptosis and necrosis in ndufs4-/- and 
WT MEFs, as well as ndufs4-/- MEFs treated with 20 μM ML-SA1 for 4 h. The cells were 
subject to 2 µM staurosporine for 1 h prior to collection, as a mild cell death-inducing 
condition. Afterwards the cells were labelled with ANXA5 and propidium iodide, as above. 
Fluorescence was measured by flow cytometry; the experiment was done in triplicate. (D) 
Column plot showing that that ndufs4-/- cells present less apoptosis but more necrosis than 
the WT. Additionally, MLSA1 treatment has not effect in the apoptotic cells but significant 
increases the necrotic cells. The plot shows variation in the number of cells undergoing death 
under each condition compared to the control (fold change; scrambled=1). ANOVA p-value 
*p<0.05, **p<0.005, ***p<0.005, n.s. (E) Cell death decreases after long-term treatment with 
20 μM MLSA1 in control and RC-kd HeLa cells. Plot shows the average±s.d. of the number 
of propidium iodide-positive cells per well of a 6-well plate. Three wells per condition were 
used per experiment, and 2 independent experiments were performed. ANOVA p-value 
*p<0.05 
Figure 8. Model for the mechanism linking chronic mitochondrial deficiency with regulation of 
lysosomal function. This diagram depicts the contrast between chronic and acute 
mitochondrial malfunction. Acute mitochondrial defects result in an increase of AMPK 
activity, which promotes the pathway that activates MCOLN1 channel, while chronic 
mitochondrial malfunction, as shown by this study, results in increased FLCN, which 
represses AMPK activity resulting in decreased activity of the MCOLN1 channel. This, in 
turn, causes accumulation of Ca2+ in the lysosomes, alterations in lysosomal pH, 
enlargement of lysosomes and lysosomal malfunction. 
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